ClinicalTrials.gg
TerminatedNCT00406653Updated Sep 14, 2010Results posted

A Study of Abatacept in Patients With Active Crohn's Disease

A Phase 3 interventional study of abatacept and placebo in Crohn's Disease, sponsored by Bristol-Myers Squibb. Terminated at 101 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-09-14.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Why this study was terminated
Sponsor Decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
451
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Crohn Disease by Bristol-Myers Squibb — none open to participants now, none under way, none of them phase 3. Crohn Disease · Bristol-Myers Squibb.

Enrollment
6th of 16
451 · median 180
Started
2006
the only one that year
Phase 3
8 of 16
none open now
Registered
1st of 16
by date

Among the 16 studies in Crohn Disease by Bristol-Myers Squibb, this one is the 6th largest by enrollment, is the only one that started in 2006, is one of 8 in phase 3, and was the 1st registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

None of the 16 studies in Crohn Disease by Bristol-Myers Squibb is open now. The open studies under Crohn Disease, anywhere →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies in Crohn Disease by Bristol-Myers Squibb as a file.
02

Study summary

The purpose of this clinical research study is to learn if abatacept can improve signs and symptoms of active Crohn's Disease in patients who have not had an adequate response to other therapies. The safety of this treatment will also be studied.

03

Conditions studied

  • Crohn's Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • 18 years or older
  • have had Crohn's Disease for at least 3 months
  • moderate to severely active Crohn's Disease
  • have had an inadequate response or intolerance to other Crohn's Disease treatments
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
451 participants (actual)

Study arms

  • Experimental
    1

    4 arms for induction period 2 arms for maintenance period

    Drug: abatacept

  • Placebo comparator
    2

    4 arms for induction period 2 arms for maintenance period

    Drug: placebo

  • Other
    abatacept

    1 arm for open-label extension phase

    Drug: abatacept

Interventions

  • Dextrose 5% in water, intravenous (IV). Placebo on days Induction Period (IP)-1, IP-15,IP-29, IP-57; 3 mg/kg on days IP-1, IP-15,IP-29, IP-57; \~10 mg/kg on days IP-1, IP-15,IP-29, IP-57, or 30 mg/kg on days IP-1,IP-15 and \~10 mg/kg on days IP-29, IP-57. Induction Period 3 months Maintenance Period 12 months

    Also known as: Orencia, BMS-188667

  • Drugplacebo

    Normal saline, IV, 0 mg/kg, every 28 days. Induction Period 3 months Maintenance Period 12 months

  • \~10 mg/kg, every 28 days. Open- Label Extension Period until the drug is marketed for Crohn's Disease (CD)or the CD development program for abatacept is discontinued

    Also known as: Orencia, BMS-188667

06

What researchers measure

Primary outcomes

  1. Induction Period (IP); Number of Participants With Crohn's Disease Activity Index (CDAI)-Defined Clinical Response at Both Day IP-57 and Day IP-85

    CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to \~600 points. Clinical response=CDAI reduction ≥100 points or absolute CDAI \<150 points. Clinical remission=CDAI \<150 points. Moderate to severe disease=CDAI ≥220 and ≤450 points.

    Time frame: At both Day IP-57 (Wk 8) and Day IP-85 (Wk 12).

  2. Maintenance Period (MP); Number of Participants In CDAI-Defined Clinical Remission (CDAI <150) at Day MP-365 (12 Months)

    CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to \~600 points. Clinical response=CDAI reduction ≥100 points or absolute CDAI \<150 points. Clinical remission=CDAI \<150 points. Moderate to severe disease=CDAI ≥220 and ≤450 points.

    Time frame: Day MP-365 (12 months) of maintenance therapy

  3. Open-Label Extension Period (OL); Number of Participants With Adverse Events (AEs), Related AEs, Deaths, Serious AEs (SAEs), Related SAEs, and Discontinuation Due to AEs

    AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.

    Time frame: Between Day OL-1 and Day OL-617

  4. OL; Number of Participants With Adverse Events (AEs) of Special Interest

    AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, and opportunistic infections; autoimmune disorders; neoplasms; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion) and peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion).

    Time frame: Between Day OL-1 and Day OL-617

Secondary outcomes

  1. IP; Number of Participants in CDAI-defined Clinical Remission at Both Day IP-57 and Day IP-85 (Key Secondary Outcome)

    CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to \~600 points. Clinical response=CDAI reduction ≥100 points or absolute CDAI \<150 points. Clinical remission=CDAI \<150 points. Moderate to severe disease=CDAI ≥220 and ≤450 points.

    Time frame: At both Day IP-57 (Wk 8) and Day IP-85 (Wk 12) of induction therapy

  2. IP; Number of Participants With CDAI-Defined Clinical Response at Both Day IP-57 and Day IP-85 Analyzed by Cochran-Armitage Trend Test for Dose-Response Relationship

    CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to \~600 points. Clinical response=CDAI reduction ≥100 points or absolute CDAI \<150 points. Clinical remission=CDAI \<150 points. Moderate to severe disease=CDAI ≥220 and ≤450 points.

    Time frame: At both Day IP-57 (Wk 8) and Day IP-85 (Wk 12) of induction therapy

  3. IP; Change From Baseline to Day IP-85 In Inflammatory Bowel Disease Questionnaire (IBDQ)

    The Inflammatory Bowel Disease Questionnaire (IBDQ) consists of a self-administered 32-item questionnaire evaluating quality of life across 4 dimensional scores: Bowel, Systemic, Social and Emotional. Responses to each question can range from 1 to 7, with 1 indicating severe problem and 7 indicating normal health. The total IBDQ is computed as the sum of the responses to the individual IBDQ questions. The total score ranges between 32 to 224 with higher scores indicating a better quality of life. Change from Baseline= post-Baseline - Baseline value.

    Time frame: Baseline, Day IP-85

  4. IP; Number of Participants With Adverse Events (AEs), Related AEs, Deaths, Serious AEs (SAEs), Related SAEs, and Discontinuation Due to AEs

    AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.

    Time frame: Day IP-1 through Day IP-85

  5. IP; Number of Participants With Adverse Events (AEs) of Special Interest

    AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, and opportunistic infections; autoimmune disorders; neoplasms; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion) and peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion).

    Time frame: Day IP-1 through Day IP-85

  6. IP; Number of Participants With Positive Antibody Response to Abatacept (ABA)

    A electrochemiluminescent immunoassay screened sera for drug-specific antibodies, immunocompetition identified specific anti-ABA reactivity. Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) and Possibly immunoglobulin (Ig) category= reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing.

    Time frame: For participants treated in MP: Day IP-1 (Baseline) to Day MP-1 (Day IP-85); For participants treated in OL directly after IP: Day IP-1 to Day OL-1; For participants treated only in IP: All measurements after Day IP-1 (including follow-up visits)

  7. IP; Number of Participants With CDAI-Defined Clinical Response at Both Day IP-57 and Day IP-85 Among Participants With Inadequate Response and/or Intolerance to Anti-Tumor Necrosis Factor (TNF)

    CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to \~600 points. Clinical response=CDAI reduction ≥100 points or absolute CDAI \<150 points. Clinical remission=CDAI \<150 points. Moderate to severe disease=CDAI ≥220 and ≤450 points.

    Time frame: At both Day IP-57 (Wk 8) and Day IP-85 (Wk 12) of induction therapy

  8. IP; Number of Participants in CDAI-Defined Clinical Remission at Both Day IP-57 and Day IP-85 Among Participants With Inadequate Response and/or Intolerance to Anti-TNF

    CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to \~600 points. Clinical response=CDAI reduction ≥100 points or absolute CDAI \<150 points. Clinical remission=CDAI \<150 points. Moderate to severe disease=CDAI ≥220 and ≤450 points.

    Time frame: At both Day IP-57 (Wk 8) and Day IP-85 (Wk 12) of induction therapy

  9. IP; Number of Participants Who Are Anti-TNF-Inadequate Responders/Anti-TNF Intolerant With CDAI-Defined Clinical Response at Both Day IP-57 and Day IP-85 Analyzed by Cochran-Armitage Trend Test for Dose-Response Relationship

    CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to \~600 points. Clinical response=CDAI reduction ≥100 points or absolute CDAI \<150 points. Clinical remission=CDAI \<150 points. Moderate to severe disease=CDAI ≥220 and ≤450 points.

    Time frame: At both Day IP-57 (Wk 8) and Day IP-85 (Wk 12) of induction therapy

  10. MP; Number of Participants With Adverse Events (AEs), Related AEs, Deaths, Serious AEs (SAEs), Related SAEs, and Discontinuation Due To AEs

    AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.

    Time frame: Between Day IP-85 and Day MP-365

  11. MP; Number of Participants With Adverse Events (AEs) of Special Interest:

    AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, and opportunistic infections; autoimmune disorders; neoplasms; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion) and peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion).

    Time frame: Between Day IP-85 and Day MP-365

  12. MP; Number of Participants With Positive Antibody Response to Abatacept

    A electrochemiluminescent immunoassay screened sera for drug-specific antibodies, immunocompetition was used to identify specific anti-Abatacept reactivity. CTLA4 and Possibly Ig category= reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing.

    Time frame: For participants not entering OL: All measurements after Day MP-1 (including follow-up visits); For participants entering OL: From first measurement after Day MP-1 to Day MP-365 (Day OL-1)

  13. MP; Number of Participants With CDAI-defined Clinical Response at Day MP-365.

    CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to \~600 points. Clinical response=CDAI reduction ≥100 points or absolute CDAI \<150 points. Clinical remission=CDAI \<150 points. Moderate to severe disease=CDAI ≥220 and ≤450 points.

    Time frame: Day MP-365

  14. MP; Number of Participants in CDAI-defined Clinical Remission at Both Day MP-169 and Day MP-365

    CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to \~600 points. Clinical response=CDAI reduction ≥100 points or absolute CDAI \<150 points. Clinical remission=CDAI \<150 points. Moderate to severe disease=CDAI ≥220 and ≤450 points.

    Time frame: Day MP-169

  15. MP; Change From Baseline to Day MP-365 in Short Form-36 (SF-36)

    The SF-36 is a validated instrument measuring health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores (1) physical component summary=physical functioning, role-physical, bodily pain, and general health; (2) mental component summary=vitality, social functioning, role-emotional, and mental health. There is no total overall score; scoring is done for both subscores and summary scores. For subscores and summary scores, 0 =worst score (or quality of life) and 100=best score. Change from Baseline= post-Baseline - Baseline value.

    Time frame: Baseline, Day MP-365

  16. MP; Change From Baseline to Day MP-365 in Inflammatory Bowel Disease Questionnaire (IBDQ)

    The Inflammatory Bowel Disease Questionnaire (IBDQ) consists of a self-administered 32-item questionnaire evaluating quality of life across 4 dimensional scores: Bowel, Systemic, Social and Emotional. Responses to each question can range from 1 to 7, with 1 indicating severe problem and 7 indicating normal health. The total IBDQ is computed as the sum of the responses to the individual IBDQ questions. The total score ranges between 32 to 224 with higher scores indicating a better quality of life. Change from Baseline= post-baseline - Baseline value.

    Time frame: Baseline, Day MP-365

  17. MP; Number of Participants Who Were Not On Background Corticosteroid Therapy at Day MP-365 Among All Participants Who Received Baseline Corticosteroid Therapy

    Participants who received corticosteroid therapy (e.g. prednisone or budesonide) were to maintain a stable dose until Day MP-1. On or after Day MP-1, a recommended tapering regimen of corticosteroid therapy was planned if the participant was in remission (i.e., CDAI score \< 150), or if the participant's condition had satisfactorily improved according to investigators clinical assessment. Other CD therapy was to remain at a stable dose throughout the Maintenance Period, with the exception of decreases due to drug-related toxicities.

    Time frame: Day MP-365

  18. MP; Number of Participants Who Were Not On Background Corticosteroid Therapy at Day MP-365 Among Participants Who Received Baseline Corticosteroid Therapy and Who Achieved CDAI-Defined Clinical Remission

    CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score is based partly on entries from participant's Diary (7 days before evaluation) which is kept while on study. CDAI scores range from 0 to \~600. Clinical response=CDAI reduction ≥100 or absolute CDAI \<150. Clinical remission=CDAI \<150. Moderate to severe disease=CDAI ≥220 and ≤450.

    Time frame: Day MP-365

  19. MP; Number of Participants With CDAI-Defined Clinical Response Among Participants With Inadequate Response and/or Intolerance to Anti-Tumor Necrosis Factor (TNF)

    CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to \~600 points. Clinical response=CDAI reduction ≥100 points or absolute CDAI \<150 points. Clinical remission=CDAI \<150 points. Moderate to severe disease=CDAI ≥220 and ≤450 points.

    Time frame: Day MP-365

  20. MP; Number of Participants in CDAI-Defined Clinical Remission Among Participants With Inadequate Response and/or Intolerance to Anti-TNF

    CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to \~600 points. Clinical response=CDAI reduction ≥100 points or absolute CDAI \<150 points. Clinical remission=CDAI \<150 points. Moderate to severe disease=CDAI ≥220 and ≤450 points.

    Time frame: Day MP-365

  21. OL; Number of Participants Who Were Not On Background Corticosteroid Therapy Among All Participants Who Received Baseline Corticosteroid Therapy

    Background corticosteroid therapy included prednisone or budesonide.

    Time frame: Between Day OL-1 and Day OL-617

  22. OL; Number of Participants With CDAI-defined Clinical Response or Clinical Remission at Day OL-169

    CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to \~600 points. Clinical response=CDAI reduction ≥100 points or absolute CDAI \<150 points. Clinical remission=CDAI \<150 points. Moderate to severe disease=CDAI ≥220 and ≤450 points.

    Time frame: Day OL-169

  23. OL; Number of Participants With CDAI-defined Clinical Response or Clinical Remission at Day OL-365

    CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to \~600 points. Clinical response=CDAI reduction ≥100 points or absolute CDAI \<150 points. Clinical remission=CDAI \<150 points. Moderate to severe disease=CDAI ≥220 and ≤450 points.

    Time frame: Day OL-365

  24. OL; Number of Participants With Positive Antibody Response to Abatacept

    A electrochemiluminescent immunoassay screened sera for drug-specific antibodies, immunocompetition was used to identify specific anti-Abatacept reactivity. CTLA4 and Possibly Ig category= reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing.

    Time frame: For participants receiving OL medication, all measurements starting after Day OL-1 (including follow-up visits and at 56 and 85 days after last dose)

  25. OL; Number of Participants With Pharmacogenomic Marker Activity

    Changes in the expression of individual ribonucleic acid (RNA) transcripts were to be evaluated from whole blood using both microarray transcriptional profiling and quantitative polymerase chain reaction (PCR) methods. Peripheral RNA transcriptional profiling was to be used only to identify individual RNA transcripts that differ in expression with respect to time, treatment and outcome.

    Time frame: Between Day OL-1 and Day OL-617

07

Results

Posted Aug 31, 2010

Participant flow

Induction Period
Participant flow — Induction Period
MilestoneAbatacept (ABA) 30/~10 mg/kg, Induction Period (IP)ABA ~10 mg/kg, IPABA 3 mg/kg, IPPlacebo, IPABA ~10 mg/kg, Maintenance Period (MP)Placebo, MPABA ~10 mg/kg, Open-Label Period (OL)
Started65128130128000
Completed5094112102000
Not completed15341826000
Withdrew: Adverse event110411000
Withdrew: Lack of efficacy1114810000
Withdrew: Lost to follow-up0200000
Withdrew: Withdrawal of consent2512000
Withdrew: Subject no longer meets study criteria0002000
Withdrew: Pregnancy1000000
Withdrew: Declined participation but followup done0211000
Withdrew: Given prohibited drug0120000
Withdrew: Incarcerated0010000
Withdrew: Patient relocated0010000
Maintenance Period
Participant flow — Maintenance Period
MilestoneAbatacept (ABA) 30/~10 mg/kg, Induction Period (IP)ABA ~10 mg/kg, IPABA 3 mg/kg, IPPlacebo, IPABA ~10 mg/kg, Maintenance Period (MP)Placebo, MPABA ~10 mg/kg, Open-Label Period (OL)
Started000044460
Completed000014100
Not completed000030360
Withdrew: Adverse event0000110
Withdrew: Lack of efficacy000020260
Withdrew: Lost to follow-up0000210
Withdrew: Withdrawal of consent0000200
Withdrew: Pregnancy0000010
Withdrew: Administrative reason by sponsor0000470
Withdrew: Error in disease score evaluation0000100
Open-Label Period
Participant flow — Open-Label Period
MilestoneAbatacept (ABA) 30/~10 mg/kg, Induction Period (IP)ABA ~10 mg/kg, IPABA 3 mg/kg, IPPlacebo, IPABA ~10 mg/kg, Maintenance Period (MP)Placebo, MPABA ~10 mg/kg, Open-Label Period (OL)
Started000000324
Completed0000000
Not completed000000324
Withdrew: Death0000001
Withdrew: Adverse event00000018
Withdrew: Lack of efficacy000000160
Withdrew: Lost to follow-up0000006
Withdrew: Withdrawal of consent00000011
Withdrew: Subject no longer meets study criteria0000001
Withdrew: Pregnancy0000002
Withdrew: Administrative reason by sponsor000000115
Withdrew: Declined participation but followup done0000008
Withdrew: Discontinued by sponsor0000001
Withdrew: Refused followup0000001

Outcome measures

PrimaryInduction Period (IP); Number of Participants With Crohn's Disease Activity Index (CDAI)-Defined Clinical Response at Both Day IP-57 and Day IP-85

CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to \~600 points. Clinical response=CDAI reduction ≥100 points or absolute CDAI \<150 points. Clinical remission=CDAI \<150 points. Moderate to severe disease=CDAI ≥220 and ≤450 points.

Time frame:
At both Day IP-57 (Wk 8) and Day IP-85 (Wk 12).
Reported as:
Number · participants
Induction Period (IP); Number of Participants With Crohn's Disease Activity Index (CDAI)-Defined Clinical Response at Both Day IP-57 and Day IP-85
participantsABA 30/~10 mg/kg, IPABA ~10 mg/kg, IPABA 3 mg/kg, IPPlacebo, IP
Induction Period (IP); Number of Participants With Crohn's Disease Activity Index (CDAI)-Defined Clinical Response at Both Day IP-57 and Day IP-8511132018
Statistical analysis
  • ABA 30/~10 mg/kg, IP vs Placebo, IP · Cochran-Mantel-Haenszel · p = 0.611 (Due to randomization misspecification, 2:2:2:1 ratio applied instead of planned 2:1:2:2 (placebo, ABA 3mg/kg, \~10mg/kg, 30/\~10mg/kg). Only \~half intended number assigned to ABA 30/\~10 mg/kg arm and \~double intended number assigned to ABA 3 mg/kg arm) · Risk ratio (rr): 1.2 · 95% CI 0.6 to 2.4All participants who prematurely discontinued for any reason considered not to have achieved clinical response. Normal approximation used if number of responses in treatment group was ≥5. Otherwise an exact method was used.
PrimaryMaintenance Period (MP); Number of Participants In CDAI-Defined Clinical Remission (CDAI <150) at Day MP-365 (12 Months)

CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to \~600 points. Clinical response=CDAI reduction ≥100 points or absolute CDAI \<150 points. Clinical remission=CDAI \<150 points. Moderate to severe disease=CDAI ≥220 and ≤450 points.

Time frame:
Day MP-365 (12 months) of maintenance therapy
Reported as:
Number · participants
Maintenance Period (MP); Number of Participants In CDAI-Defined Clinical Remission (CDAI <150) at Day MP-365 (12 Months)
participantsABA ~10 mg/kg, MPPlacebo, MP
Maintenance Period (MP); Number of Participants In CDAI-Defined Clinical Remission (CDAI <150) at Day MP-365 (12 Months)105
PrimaryOpen-Label Extension Period (OL); Number of Participants With Adverse Events (AEs), Related AEs, Deaths, Serious AEs (SAEs), Related SAEs, and Discontinuation Due to AEs

AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.

Time frame:
Between Day OL-1 and Day OL-617
Reported as:
Number · participants
Open-Label Extension Period (OL); Number of Participants With Adverse Events (AEs), Related AEs, Deaths, Serious AEs (SAEs), Related SAEs, and Discontinuation Due to AEs
participantsABA ~10 mg/kg, OL
AEs267
Related AEs128
Deaths1
SAEs86
Related SAEs21
Discontinuation due to AE16
SecondaryIP; Number of Participants in CDAI-defined Clinical Remission at Both Day IP-57 and Day IP-85 (Key Secondary Outcome)

CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to \~600 points. Clinical response=CDAI reduction ≥100 points or absolute CDAI \<150 points. Clinical remission=CDAI \<150 points. Moderate to severe disease=CDAI ≥220 and ≤450 points.

Time frame:
At both Day IP-57 (Wk 8) and Day IP-85 (Wk 12) of induction therapy
Reported as:
Number · participants
IP; Number of Participants in CDAI-defined Clinical Remission at Both Day IP-57 and Day IP-85 (Key Secondary Outcome)
participantsABA 30/~10 mg/kg, IPABA ~10 mg/kg, IPABA 3 mg/kg, IPPlacebo, IP
IP; Number of Participants in CDAI-defined Clinical Remission at Both Day IP-57 and Day IP-85 (Key Secondary Outcome)5568
Statistical analysis
  • ABA 30/~10 mg/kg, IP vs Placebo, IP · Cochran-Mantel-Haenszel · Risk ratio (rr): 1.18 · 95% CI 0.4 to 3.44All participants who prematurely discontinued for any reason considered not to have achieved clinical response. Normal approximation used if number of responses in treatment group was ≥5. Otherwise an exact method was used.
SecondaryIP; Number of Participants With CDAI-Defined Clinical Response at Both Day IP-57 and Day IP-85 Analyzed by Cochran-Armitage Trend Test for Dose-Response Relationship

CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to \~600 points. Clinical response=CDAI reduction ≥100 points or absolute CDAI \<150 points. Clinical remission=CDAI \<150 points. Moderate to severe disease=CDAI ≥220 and ≤450 points.

Time frame:
At both Day IP-57 (Wk 8) and Day IP-85 (Wk 12) of induction therapy
Reported as:
Number · participants
IP; Number of Participants With CDAI-Defined Clinical Response at Both Day IP-57 and Day IP-85 Analyzed by Cochran-Armitage Trend Test for Dose-Response Relationship
participantsPlacebo, IPABA 3 mg/kg, IPABA ~10 mg/kg, IPABA 30/~10 mg/kg, IP
IP; Number of Participants With CDAI-Defined Clinical Response at Both Day IP-57 and Day IP-85 Analyzed by Cochran-Armitage Trend Test for Dose-Response Relationship18201311
Statistical analysis
  • Placebo, IP vs ABA 3 mg/kg, IP vs ABA ~10 mg/kg, IP vs ABA 30/~10 mg/kg, IP · Cochran-Armitage Trend Test · p = 0.436 (All statistical testing was performed at a pre-specified alpha-level of 5%.)
SecondaryIP; Change From Baseline to Day IP-85 In Inflammatory Bowel Disease Questionnaire (IBDQ)

The Inflammatory Bowel Disease Questionnaire (IBDQ) consists of a self-administered 32-item questionnaire evaluating quality of life across 4 dimensional scores: Bowel, Systemic, Social and Emotional. Responses to each question can range from 1 to 7, with 1 indicating severe problem and 7 indicating normal health. The total IBDQ is computed as the sum of the responses to the individual IBDQ questions. The total score ranges between 32 to 224 with higher scores indicating a better quality of life. Change from Baseline= post-Baseline - Baseline value.

Time frame:
Baseline, Day IP-85
Reported as:
Mean · units on a scale
IP; Change From Baseline to Day IP-85 In Inflammatory Bowel Disease Questionnaire (IBDQ)
units on a scaleABA 30/~10 mg/kg, IPABA ~10 mg/kg, IPABA 3 mg/kg, IPPlacebo, IP
IP; Change From Baseline to Day IP-85 In Inflammatory Bowel Disease Questionnaire (IBDQ)0.79 ± 3.97411.10 ± 2.8587.53 ± 2.76513.4 ± 2.798
SecondaryIP; Number of Participants With Adverse Events (AEs), Related AEs, Deaths, Serious AEs (SAEs), Related SAEs, and Discontinuation Due to AEs

AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.

Time frame:
Day IP-1 through Day IP-85
Reported as:
Number · Participants
IP; Number of Participants With Adverse Events (AEs), Related AEs, Deaths, Serious AEs (SAEs), Related SAEs, and Discontinuation Due to AEs
ParticipantsABA 30/~10 mg/kg, IPABA ~10 mg/kg, IPABA 3 mg/kg, IPPlacebo, IP
AEs49979695
Related AEs24474640
Deaths0000
SAEs11222020
Related SAEs2796
Discontinuation due to AE111512
SecondaryIP; Number of Participants With Adverse Events (AEs) of Special Interest

AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, and opportunistic infections; autoimmune disorders; neoplasms; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion) and peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion).

Time frame:
Day IP-1 through Day IP-85
Reported as:
Number · participants
IP; Number of Participants With Adverse Events (AEs) of Special Interest
participantsABA 30/~10 mg/kg, IPABA ~10 mg/kg, IPABA 3 mg/kg, IPPlacebo, IP
All Infections13333142
Serious Infections2943
Opportunistic Infections0000
Malignancies-Total0030
Malignancies-squamous cell carcinoma0020
Malignancies-breast cancer0010
Autoimmune Disorders-Total2122
Autoimmune Disorders-erythema2121
Autoimmune Disorders-psoriasis0001
Acute Infusional AEs3345
Peri-infusional AEs13221516
SecondaryIP; Number of Participants With Positive Antibody Response to Abatacept (ABA)

A electrochemiluminescent immunoassay screened sera for drug-specific antibodies, immunocompetition identified specific anti-ABA reactivity. Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) and Possibly immunoglobulin (Ig) category= reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing.

Time frame:
For participants treated in MP: Day IP-1 (Baseline) to Day MP-1 (Day IP-85); For participants treated in OL directly after IP: Day IP-1 to Day OL-1; For participants treated only in IP: All measurements after Day IP-1 (including follow-up visits)
Reported as:
Number · participants
IP; Number of Participants With Positive Antibody Response to Abatacept (ABA)
participantsABA 30/~10 mg/kg, IPABA ~10 mg/kg, IPABA 3 mg/kg, IP
Total4712
CTLA4/Possibly Ig106
Ig and/or Ig Junction376
SecondaryIP; Number of Participants With CDAI-Defined Clinical Response at Both Day IP-57 and Day IP-85 Among Participants With Inadequate Response and/or Intolerance to Anti-Tumor Necrosis Factor (TNF)

CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to \~600 points. Clinical response=CDAI reduction ≥100 points or absolute CDAI \<150 points. Clinical remission=CDAI \<150 points. Moderate to severe disease=CDAI ≥220 and ≤450 points.

Time frame:
At both Day IP-57 (Wk 8) and Day IP-85 (Wk 12) of induction therapy
Reported as:
Number · participants
IP; Number of Participants With CDAI-Defined Clinical Response at Both Day IP-57 and Day IP-85 Among Participants With Inadequate Response and/or Intolerance to Anti-Tumor Necrosis Factor (TNF)
participantsABA 30/~10 mg/kg, IPABA ~10 mg/kg, IPABA 3 mg/kg, IPPlacebo, IP
IP; Number of Participants With CDAI-Defined Clinical Response at Both Day IP-57 and Day IP-85 Among Participants With Inadequate Response and/or Intolerance to Anti-Tumor Necrosis Factor (TNF)98210
SecondaryIP; Number of Participants in CDAI-Defined Clinical Remission at Both Day IP-57 and Day IP-85 Among Participants With Inadequate Response and/or Intolerance to Anti-TNF

CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to \~600 points. Clinical response=CDAI reduction ≥100 points or absolute CDAI \<150 points. Clinical remission=CDAI \<150 points. Moderate to severe disease=CDAI ≥220 and ≤450 points.

Time frame:
At both Day IP-57 (Wk 8) and Day IP-85 (Wk 12) of induction therapy
Reported as:
Number · participants
IP; Number of Participants in CDAI-Defined Clinical Remission at Both Day IP-57 and Day IP-85 Among Participants With Inadequate Response and/or Intolerance to Anti-TNF
participantsABA 30/~10 mg/kg, IPABA ~10 mg/kg, IPABA 3 mg/kg, IPPlacebo, IP
IP; Number of Participants in CDAI-Defined Clinical Remission at Both Day IP-57 and Day IP-85 Among Participants With Inadequate Response and/or Intolerance to Anti-TNF3203
SecondaryIP; Number of Participants Who Are Anti-TNF-Inadequate Responders/Anti-TNF Intolerant With CDAI-Defined Clinical Response at Both Day IP-57 and Day IP-85 Analyzed by Cochran-Armitage Trend Test for Dose-Response Relationship

CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to \~600 points. Clinical response=CDAI reduction ≥100 points or absolute CDAI \<150 points. Clinical remission=CDAI \<150 points. Moderate to severe disease=CDAI ≥220 and ≤450 points.

Time frame:
At both Day IP-57 (Wk 8) and Day IP-85 (Wk 12) of induction therapy
Reported as:
Number · participants
IP; Number of Participants Who Are Anti-TNF-Inadequate Responders/Anti-TNF Intolerant With CDAI-Defined Clinical Response at Both Day IP-57 and Day IP-85 Analyzed by Cochran-Armitage Trend Test for Dose-Response Relationship
participantsPlacebo, IPABA 3 mg/kg, IPABA ~10 mg/kg, IPABA 30/~10 mg/kg, IP
IP; Number of Participants Who Are Anti-TNF-Inadequate Responders/Anti-TNF Intolerant With CDAI-Defined Clinical Response at Both Day IP-57 and Day IP-85 Analyzed by Cochran-Armitage Trend Test for Dose-Response Relationship10289
Statistical analysis
  • Placebo, IP vs ABA 3 mg/kg, IP vs ABA ~10 mg/kg, IP vs ABA 30/~10 mg/kg, IP · Cochran-Armitage Trend Test · p = 0.112 (All statistical testing was performed at a pre-specified alpha-level of 5%.)
SecondaryMP; Number of Participants With Adverse Events (AEs), Related AEs, Deaths, Serious AEs (SAEs), Related SAEs, and Discontinuation Due To AEs

AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.

Time frame:
Between Day IP-85 and Day MP-365
Reported as:
Number · Participants
MP; Number of Participants With Adverse Events (AEs), Related AEs, Deaths, Serious AEs (SAEs), Related SAEs, and Discontinuation Due To AEs
ParticipantsABA ~10 mg/kg, MPPlacebo, MP
AEs3132
Related AEs1215
Deaths00
SAEs59
Related SAEs01
Discontinuation due to AE10
SecondaryMP; Number of Participants With Adverse Events (AEs) of Special Interest:

AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, and opportunistic infections; autoimmune disorders; neoplasms; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion) and peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion).

Time frame:
Between Day IP-85 and Day MP-365
Reported as:
Number · participants
MP; Number of Participants With Adverse Events (AEs) of Special Interest:
participantsABA ~10 mg/kg, MPPlacebo, MP
All Infections1618
Serious Infections11
Opportunistic Infections00
Malignancies00
Autoimmune Disorders-Total21
Autoimmune Disorders-psoriasis20
Autoimmune Disorders-erythema01
Acute Infusional AEs10
Peri-infusional AEs20
SecondaryMP; Number of Participants With Positive Antibody Response to Abatacept

A electrochemiluminescent immunoassay screened sera for drug-specific antibodies, immunocompetition was used to identify specific anti-Abatacept reactivity. CTLA4 and Possibly Ig category= reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing.

Time frame:
For participants not entering OL: All measurements after Day MP-1 (including follow-up visits); For participants entering OL: From first measurement after Day MP-1 to Day MP-365 (Day OL-1)
Reported as:
Number · participants
MP; Number of Participants With Positive Antibody Response to Abatacept
participantsABA ~10 mg/kg, MPPlacebo, MP
Total714
CTLA4/Possibly Ig28
Ig and/or Ig Junction58
SecondaryMP; Number of Participants With CDAI-defined Clinical Response at Day MP-365.

CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to \~600 points. Clinical response=CDAI reduction ≥100 points or absolute CDAI \<150 points. Clinical remission=CDAI \<150 points. Moderate to severe disease=CDAI ≥220 and ≤450 points.

Time frame:
Day MP-365
Reported as:
Number · participants
MP; Number of Participants With CDAI-defined Clinical Response at Day MP-365.
participantsABA ~10 mg/kg, MPPlacebo, MP
MP; Number of Participants With CDAI-defined Clinical Response at Day MP-365.117
PrimaryOL; Number of Participants With Adverse Events (AEs) of Special Interest

AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, and opportunistic infections; autoimmune disorders; neoplasms; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion) and peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion).

Time frame:
Between Day OL-1 and Day OL-617
Reported as:
Number · participants
OL; Number of Participants With Adverse Events (AEs) of Special Interest
participantsABA ~10 mg/kg, OL
All Infections144
Serious Infections13
Opportunistic Infections (OI)-Total2
OI-oral candidiasis1
OI-gastroenteritis Cryptosporidial1
Malignancies-Total5
Malignancies-basal cell carcinoma2
Malignancies-breast cancer1
Malignancies-squamous cell carcinoma1
Malignancies-chronic lymphocytic leukemia1
Autoimmune Disorders-Total11
Autoimmune Disorders-erythema nodosum7
Autoimmune Disorders-psoriasis1
Autoimmune Disorders-pernicious anemia1
Autoimmune Disorders-antiphospholipid syndrome1
Autoimmune Disorders-ankylosing spondylitis1
Acute Infusional AEs10
Peri-infusional AEs24
SecondaryMP; Number of Participants in CDAI-defined Clinical Remission at Both Day MP-169 and Day MP-365

CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to \~600 points. Clinical response=CDAI reduction ≥100 points or absolute CDAI \<150 points. Clinical remission=CDAI \<150 points. Moderate to severe disease=CDAI ≥220 and ≤450 points.

Time frame:
Day MP-169
Reported as:
Number · participants

No measurements were reported for this outcome.

SecondaryMP; Change From Baseline to Day MP-365 in Short Form-36 (SF-36)

The SF-36 is a validated instrument measuring health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores (1) physical component summary=physical functioning, role-physical, bodily pain, and general health; (2) mental component summary=vitality, social functioning, role-emotional, and mental health. There is no total overall score; scoring is done for both subscores and summary scores. For subscores and summary scores, 0 =worst score (or quality of life) and 100=best score. Change from Baseline= post-Baseline - Baseline value.

Time frame:
Baseline, Day MP-365
Reported as:
Mean · units on a scale

No measurements were reported for this outcome.

SecondaryMP; Change From Baseline to Day MP-365 in Inflammatory Bowel Disease Questionnaire (IBDQ)

The Inflammatory Bowel Disease Questionnaire (IBDQ) consists of a self-administered 32-item questionnaire evaluating quality of life across 4 dimensional scores: Bowel, Systemic, Social and Emotional. Responses to each question can range from 1 to 7, with 1 indicating severe problem and 7 indicating normal health. The total IBDQ is computed as the sum of the responses to the individual IBDQ questions. The total score ranges between 32 to 224 with higher scores indicating a better quality of life. Change from Baseline= post-baseline - Baseline value.

Time frame:
Baseline, Day MP-365
Reported as:
Mean · units on a scale

No measurements were reported for this outcome.

SecondaryMP; Number of Participants Who Were Not On Background Corticosteroid Therapy at Day MP-365 Among All Participants Who Received Baseline Corticosteroid Therapy

Participants who received corticosteroid therapy (e.g. prednisone or budesonide) were to maintain a stable dose until Day MP-1. On or after Day MP-1, a recommended tapering regimen of corticosteroid therapy was planned if the participant was in remission (i.e., CDAI score \< 150), or if the participant's condition had satisfactorily improved according to investigators clinical assessment. Other CD therapy was to remain at a stable dose throughout the Maintenance Period, with the exception of decreases due to drug-related toxicities.

Time frame:
Day MP-365
Reported as:
Number · participants

No measurements were reported for this outcome.

SecondaryMP; Number of Participants Who Were Not On Background Corticosteroid Therapy at Day MP-365 Among Participants Who Received Baseline Corticosteroid Therapy and Who Achieved CDAI-Defined Clinical Remission

CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score is based partly on entries from participant's Diary (7 days before evaluation) which is kept while on study. CDAI scores range from 0 to \~600. Clinical response=CDAI reduction ≥100 or absolute CDAI \<150. Clinical remission=CDAI \<150. Moderate to severe disease=CDAI ≥220 and ≤450.

Time frame:
Day MP-365
Reported as:
Number · participants

No measurements were reported for this outcome.

SecondaryMP; Number of Participants With CDAI-Defined Clinical Response Among Participants With Inadequate Response and/or Intolerance to Anti-Tumor Necrosis Factor (TNF)

CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to \~600 points. Clinical response=CDAI reduction ≥100 points or absolute CDAI \<150 points. Clinical remission=CDAI \<150 points. Moderate to severe disease=CDAI ≥220 and ≤450 points.

Time frame:
Day MP-365
Reported as:
Number · participants

No measurements were reported for this outcome.

SecondaryMP; Number of Participants in CDAI-Defined Clinical Remission Among Participants With Inadequate Response and/or Intolerance to Anti-TNF

CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to \~600 points. Clinical response=CDAI reduction ≥100 points or absolute CDAI \<150 points. Clinical remission=CDAI \<150 points. Moderate to severe disease=CDAI ≥220 and ≤450 points.

Time frame:
Day MP-365
Reported as:
Number · participants

No measurements were reported for this outcome.

SecondaryOL; Number of Participants Who Were Not On Background Corticosteroid Therapy Among All Participants Who Received Baseline Corticosteroid Therapy

Background corticosteroid therapy included prednisone or budesonide.

Time frame:
Between Day OL-1 and Day OL-617
Reported as:
Number · participants

No measurements were reported for this outcome.

SecondaryOL; Number of Participants With CDAI-defined Clinical Response or Clinical Remission at Day OL-169

CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to \~600 points. Clinical response=CDAI reduction ≥100 points or absolute CDAI \<150 points. Clinical remission=CDAI \<150 points. Moderate to severe disease=CDAI ≥220 and ≤450 points.

Time frame:
Day OL-169
Reported as:
Number · participants
OL; Number of Participants With CDAI-defined Clinical Response or Clinical Remission at Day OL-169
participantsABA ~10 mg/kg, OL
Clinical Response84
Clinical Remission55
SecondaryOL; Number of Participants With CDAI-defined Clinical Response or Clinical Remission at Day OL-365

CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to \~600 points. Clinical response=CDAI reduction ≥100 points or absolute CDAI \<150 points. Clinical remission=CDAI \<150 points. Moderate to severe disease=CDAI ≥220 and ≤450 points.

Time frame:
Day OL-365
Reported as:
Number · participants
OL; Number of Participants With CDAI-defined Clinical Response or Clinical Remission at Day OL-365
participantsABA ~10 mg/kg, OL
Clinical Response35
Clinical Remission24
SecondaryOL; Number of Participants With Positive Antibody Response to Abatacept

A electrochemiluminescent immunoassay screened sera for drug-specific antibodies, immunocompetition was used to identify specific anti-Abatacept reactivity. CTLA4 and Possibly Ig category= reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing.

Time frame:
For participants receiving OL medication, all measurements starting after Day OL-1 (including follow-up visits and at 56 and 85 days after last dose)
Reported as:
Number · participants
OL; Number of Participants With Positive Antibody Response to Abatacept
participantsABA ~10 mg/kg, OL
Total71
CTLA4/Possibly Ig46
Ig and/or Ig Junction29
SecondaryOL; Number of Participants With Pharmacogenomic Marker Activity

Changes in the expression of individual ribonucleic acid (RNA) transcripts were to be evaluated from whole blood using both microarray transcriptional profiling and quantitative polymerase chain reaction (PCR) methods. Peripheral RNA transcriptional profiling was to be used only to identify individual RNA transcripts that differ in expression with respect to time, treatment and outcome.

Time frame:
Between Day OL-1 and Day OL-617
Reported as:
Number · participants

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ABA 30/~10mg/kg (IP)—11/65 (16.9%)34/65 (52.3%)
ABA 3mg/kg (IP)—20/130 (15.4%)48/130 (36.9%)
ABA ~10mg/kg (IP)—22/128 (17.2%)45/128 (35.2%)
ABA ~10mg/kg (MP)—5/44 (11.4%)19/44 (43.2%)
ABA ~10mg/kg (OL)—86/324 (26.5%)150/324 (46.3%)
Placebo (IP)—20/128 (15.6%)60/128 (46.9%)
Placebo (MP)—9/46 (19.6%)17/46 (37%)
Most frequent serious events
Showing 10 of 92
Most frequent serious events
EventABA 30/~10mg/kg (IP)ABA 3mg/kg (IP)ABA ~10mg/kg (IP)ABA ~10mg/kg (MP)ABA ~10mg/kg (OL)Placebo (IP)Placebo (MP)
CROHN'S DISEASEGastrointestinal disorders5/659/1309/1282/4435/32410/1283/46
ANAL ABSCESSInfections and infestations0/653/1304/1280/443/3241/1280/46
ABDOMINAL PAINGastrointestinal disorders0/652/1300/1281/443/3240/1280/46
BRONCHITISInfections and infestations1/650/1300/1281/440/3240/1280/46
CALCULUS URETERICRenal and urinary disorders0/650/1301/1281/440/3240/1280/46
ROAD TRAFFIC ACCIDENTInjury, poisoning and procedural complications0/650/1300/1281/440/3240/1280/46
ANAL FISTULAGastrointestinal disorders0/650/1300/1280/441/3240/1281/46
GASTROINTESTINAL HAEMORRHAGEGastrointestinal disorders0/650/1300/1280/440/3240/1281/46
SMALL INTESTINAL OBSTRUCTIONGastrointestinal disorders1/650/1301/1280/443/3240/1281/46
CLOSTRIDIUM DIFFICILE COLITISInfections and infestations1/650/1300/1280/443/3240/1281/46
Most frequent other events
Showing 10 of 15
Most frequent other events
EventABA 30/~10mg/kg (IP)ABA 3mg/kg (IP)ABA ~10mg/kg (IP)ABA ~10mg/kg (MP)ABA ~10mg/kg (OL)Placebo (IP)Placebo (MP)
PYREXIAGeneral disorders9/654/1305/1280/4421/32410/1284/46
NAUSEAGastrointestinal disorders6/6511/1309/1285/4435/3249/1282/46
HEADACHENervous system disorders7/6512/13013/1282/4430/3248/1283/46
ARTHRALGIAMusculoskeletal and connective tissue disorders7/659/1307/1283/4427/3248/1283/46
VOMITINGGastrointestinal disorders5/653/1302/1283/4423/3248/1284/46
NASOPHARYNGITISInfections and infestations1/657/1302/1281/4425/3245/1284/46
ABDOMINAL PAINGastrointestinal disorders4/653/1307/1283/4426/3247/1283/46
FATIGUEGeneral disorders5/658/1304/1283/4422/32410/1280/46
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations1/655/1300/1283/4425/3246/1283/46
MOUTH ULCERATIONGastrointestinal disorders1/651/1301/1283/443/3240/1280/46

Baseline characteristics

Age Continuous
Age Continuous(years)ABA 30/~10 mg/kg, Induction Period (IP)ABA ~10 mg/kg, IPABA 3 mg/kg, IPPlacebo, IPTotal
Mean36.0 ± 11.1238.6 ± 12.9036.9 ± 13.3538.0 ± 12.9837.6 ± 12.81
Age, Customized
Age, Customized(Participants)ABA 30/~10 mg/kg, Induction Period (IP)ABA ~10 mg/kg, IPABA 3 mg/kg, IPPlacebo, IPTotal
<30 years23375141152
Between 30 and 50 years35645764220
>50 years727222379
Sex: Female, Male
Sex: Female, Male(Participants)ABA 30/~10 mg/kg, Induction Period (IP)ABA ~10 mg/kg, IPABA 3 mg/kg, IPPlacebo, IPTotal
Female38787883277
Male27505245174
Region of Enrollment
Region of Enrollment(participants)ABA 30/~10 mg/kg, Induction Period (IP)ABA ~10 mg/kg, IPABA 3 mg/kg, IPPlacebo, IPTotal
United States24454638153
Italy055515
Switzerland243110
India13228
France687728
Czech Republic12025
Mexico14038
Puerto Rico10023
Canada818222775
Brazil376622
Belgium2791331
Korea, Democratic People's Republic of11114
Denmark1410217
Australia610131342
South Africa551213
Germany02237
Netherlands333110
Inadequate Response/Intolerance to Prior Anti-Tumor Necrosis Factor (TNF) Agent Therapy
Inadequate Response/Intolerance to Prior Anti-Tumor Necrosis Factor (TNF) Agent Therapy(Participants)ABA 30/~10 mg/kg, Induction Period (IP)ABA ~10 mg/kg, IPABA 3 mg/kg, IPPlacebo, IPTotal
Inadequate Response/Intolerance To Prior Agents42867777282
No Inadequate Response/Intolerance To Prior Agents23425351169
Crohn's Disease (CD) Duration
Crohn's Disease (CD) Duration(Years)ABA 30/~10 mg/kg, Induction Period (IP)ABA ~10 mg/kg, IPABA 3 mg/kg, IPPlacebo, IPTotal
Mean8.4 ± 7.499.9 ± 8.749.2 ± 7.989.8 ± 8.299.5 ± 8.21
Crohn's Disease Activity Index (CDAI)
Crohn's Disease Activity Index (CDAI)(points)ABA 30/~10 mg/kg, Induction Period (IP)ABA ~10 mg/kg, IPABA 3 mg/kg, IPPlacebo, IPTotal
Mean320.6 ± 61.59318.9 ± 65.08317.9 ± 59.87320.7 ± 72.09319.4 ± 65.03
Inflammatory Bowel Disease Questionnaire (IBDQ) Score
Inflammatory Bowel Disease Questionnaire (IBDQ) Score(units on a scale)ABA 30/~10 mg/kg, Induction Period (IP)ABA ~10 mg/kg, IPABA 3 mg/kg, IPPlacebo, IPTotal
Mean119.9 ± 26.22117.3 ± 30.60121.1 ± 28.0119.6 ± 31.17119.5 ± 29.36
08

Study locations

101 sites
  • University Of Alabama Medical Center
    Birmingham, Alabama 35294, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • The Permanente Medical Group, Inc
    Sacramento, California 95825, United States
  • University Of Florida
    Gainesville, Florida 32610, United States
  • Borland-Groover Clinic
    Jacksonville, Florida 32256, United States
  • Shafran Gasteroenterology Center
    Winter Park, Florida 32789, United States
  • Atlanta Gastroenterology Associates
    Atlanta, Georgia 30342, United States
  • University Of Chicago Hospitals
    Chicago, Illinois 60637, United States
  • Health Science Center
    Pratt, Kansas 67124, United States
  • University Of Kentucky Medical Center
    Lexington, Kentucky 40536, United States
  • University Of Louisville
    Louisville, Kentucky 40202, United States
  • Gulf Coast Research Assoc
    Baton Rouge, Louisiana 70808, United States
  • Vanderlick, Michael
    Lafayette, Louisiana 70506, United States
  • Maryland Digestive Disease Research
    Laurel, Maryland 20707, United States
  • Minnesota Gastroenterology, P.A.
    Plymouth, Minnesota 55446, United States
  • Mayo Clinic Rochester
    Rochester, Minnesota 55905, United States
  • Kansas City Gastroenterology And Hepatology
    Kansas City, Missouri 64131, United States
  • Aga Clinical Research Associates, Llc
    Egg Harbor Twp, New Jersey 08234, United States
  • Long Island Clinical Research
    Great Neck, New York 11021, United States
  • Mount Sinai School Of Medicine
    New York, New York 10029, United States
  • U Of Rochester Gastroenterology And Hepatology
    Rochester, New York 14642, United States
  • University Endoscopy Center
    Syracuse, New York 13210, United States
  • University Of North Carolina At Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • Charlotte Gastroenterology & Hepatology, Pllc
    Charlotte, North Carolina 28207, United States
  • Piedmont Medical Research Associates
    Winston Salem, North Carolina 27103, United States
  • Gastroenterology Specialists, Inc.
    Canton, Ohio 44718, United States
  • Consultants For Clinical Research
    Cincinnati, Ohio 45219, United States
  • Gastrointestinal & Liver Diseases Consultants
    Dayton, Ohio 45415, United States
  • Options Health Research, Llc
    Tulsa, Oklahoma 74104, United States
  • Allegheny Center For Digestive Health
    Pittsburgh, Pennsylvania 15212, United States
  • Southeastern Clinical Research
    Chattanooga, Tennessee 37403, United States
  • Gastroenterology Center Of The Midsouth, P.C.
    Germantown, Tennessee 38138, United States
  • Memphis Gastroenterology Group
    Germantown, Tennessee 38138, United States
  • Nashville Medical Research
    Nashville, Tennessee 37205, United States
  • Austin Gastroenterology, Pa
    Austin, Texas 78705, United States
  • Gastroenterology Clinic Of San Antonio
    San Antonio, Texas 78229, United States
  • Virginia Mason Medical Center
    Seattle, Washington 98101, United States
  • Local Institution
    Garran, Australian Capital Territory 2605, Australia
  • Local Institution
    Camperdown, New South Wales 2050, Australia
  • Local Institution
    Herston, Queensland 4029, Australia
  • Local Institution
    South Brisbane, Queensland 4101, Australia
  • Local Institution
    Bedford Park, South Australia 5042, Australia
  • Local Institution
    Launceston, Tasmania 7250, Australia
  • Local Institution
    Box Hill, Victoria 3128, Australia
  • Local Institution
    Fitzroy, Victoria 3065 VIC, Australia
  • Local Institution
    South Ballarat, Victoria 3350, Australia
  • Local Institution
    Fremantle, Western Australia 6160, Australia
  • Local Institution
    Bonheiden, 2820, Belgium
  • Local Institution
    Leuven, 3000, Belgium
  • Local Institution
    Roeselare, 8800, Belgium
  • Local Institution
    Salvador, Bahia 42700, Brazil
  • Local Institution
    Goiania, Goias 74535, Brazil
  • Local Institution
    Curitiba, Parana 80060, Brazil
  • Local Institution
    Porto Alegre, Rio Grande Do Sul 90035, Brazil
  • Local Institution
    Sao Paulo, 01246, Brazil
  • Local Institution
    Calgary, Alberta T2N 4N1, Canada
  • Local Institution
    Edmonton, Alberta T6G 2X8, Canada
  • Local Institution
    Vancouver, British Columbia V6Z 2K5, Canada
  • Local Institution
    St Johns, Newfoundland and Labrador A1B 3V6, Canada
  • Local Institution
    Halifax, Nova Scotia B3H 2Y9, Canada
  • Local Institution
    London, Ontario N6A 5A5, Canada
  • Local Institution
    Ottawa, Ontario K1H 8L6, Canada
  • Local Institution
    Toronto, Ontario M3N 2V7, Canada
  • Local Institution
    Montreal, Quebec H1T 2M4, Canada
  • Local Institution
    Ceske Budejovice, 370 87, Czech Republic
  • Local Institution
    Aalborg, 9100, Denmark
  • Local Institution
    Arhus C, 8000, Denmark
  • Local Institution
    Hvidovre, 2650, Denmark
  • Local Institution
    Odense C, 5000, Denmark
  • Local Institution
    Amiens Cedex 1, 80054, France
  • Local Institution
    Lille Cedex, 59037, France
  • Local Institution
    Nice, 06200, France
  • Local Institution
    Paris Cedex 10, 75475, France
  • Local Institution
    Pessac, 33064, France
  • Local Institution
    Toulouse Cedex, 31059, France
  • Local Institution
    Kiel, 24105, Germany
  • Local Institution
    Muenster, 48129, Germany
  • Local Institution
    Muenster, 48159, Germany
  • Local Institution
    Hyderabad, Andhra Pradesh 500082, India
  • Local Institution
    Hyderabad, 500058, India
  • Local Institution
    Mangalore, 575001, India
  • Local Institution
    Manipal, 576104, India
  • Local Institution
    Mumbai, 400 029, India
  • Local Institution
    Mysore, 570004, India
  • Local Institution
    Napoli, 80138, Italy
  • Local Institution
    Padova, 35128, Italy
  • Local Institution
    Roma, 00152, Italy
  • Local Institution
    San Giovanni Rotondo, 71013, Italy
  • Local Institution
    Torreon, Coahuila 27250, Mexico
  • Local Institution
    Mexico, D.F., Distrito Federal 14000, Mexico
  • Local Institution
    Monterrey, Nuevo Leon 64460, Mexico
  • Local Institution
    Amsterdam, 1105 AZ, Netherlands
  • Local Institution
    Groningen, 9713 GZ, Netherlands
  • Local Institution
    Rotterdam, 3015 CE, Netherlands
  • Local Institution
    Katowice, 40-752, Poland
  • Local Institution
    Ponce, 00716, Puerto Rico
  • Local Institution
    Overport, Kwa Zulu Natal 4091, South Africa
  • Local Institution
    Belville, Western Cape 7535, South Africa
  • Local Institution
    Bern, 3010, Switzerland
  • Local Institution
    Lausanne, 1011, Switzerland

Showing the first 100 of 101 sites across 17 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Sandborn WJ, Colombel JF, Sands BE, Rutgeerts P, Targan SR, Panaccione R, Bressler B, Geboes K, Schreiber S, Aranda R, Gujrathi S, Luo A, Peng Y, Salter-Cid L, Hanauer SB. Abatacept for Crohn's disease and ulcerative colitis. Gastroenterology. 2012 Jul;143(1):62-69.e4. doi: 10.1053/j.gastro.2012.04.010. Epub 2012 Apr 12. PubMed 22504093 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2006, a primary completion of Nov 2009 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2010, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2006
First posted
Dec 4, 2006
Start
Dec 2006
Primary completionActual
Nov 2009
CompletionActual
Nov 2009
Results first posted
Aug 31, 2010
Last update
Sep 14, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00406653
First posted
Dec 4, 2006
Start date
Dec 2006
Primary completion
Nov 2009
Completion
Nov 2009
Results posted
Aug 31, 2010
Last update
Sep 14, 2010

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abatacept

Start the discussion